cysteine has been researched along with nirmatrelvir in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ekanayake, KB; George, J; Jackson, C; Mahawaththa, MC; Morewood, R; Nitsche, C; Otting, G; Sasi, VM; Shuttleworth, L; Ullrich, S; Whitefield, C; Zhang, X | 1 |
| Brewitz, L; Carroll, MW; Crawshaw, AD; Dumjahn, L; Laidlaw, SM; Lukacik, P; Malla, TR; Nguyen, D; Owen, CD; Salah, E; Schofield, CJ; Strain-Damerell, C; Trincao, J; Walsh, MA; Warren, AJ; Zhao, Y | 1 |
2 other study(ies) available for cysteine and nirmatrelvir
| Article | Year |
|---|---|
Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors.
Topics: Coronavirus 3C Proteases; COVID-19; Cysteine; Humans; Lactams; Leucine; Nitriles; Peptides; Peptidomimetics; Proline; Protease Inhibitors; SARS-CoV-2; Structure-Activity Relationship; Substrate Specificity | 2021 |
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine.
Topics: Antiviral Agents; Coronavirus 3C Proteases; COVID-19; Cysteine; Humans; Nitriles; SARS-CoV-2; Viral Nonstructural Proteins; Viral Protease Inhibitors | 2023 |